

References

1. Canadian Tobacco Use Monitoring Survey (2010). http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_ctums-esutc_2010/ann-eng.php#t2
2. WRHA (2010). Winnipeg Regional Health Authority Community Health Assessment, 2009-2010. Winnipeg.
3. Baliunas D, Patra J, Rehm J, Popova S, Kaiserman M, & Taylor B (2007). Smoking-attributable mortality and expected years of life lost in Canada 2002: Conclusions for prevention and policy. *Chronic Diseases in Canada*, 27(4), 154-62.
4. Lasser K, Boyd JW, Woolhandler S, Himmelstein, DU, McCormick D, & bor DH (2000). Smoking and mental illness: A population-based prevalence study. *The Journal of the American Medical Association*, 284(20), 2606-10.
5. Zideonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, Breslau N, Brown RA, George TP, Williams J, Calhoun PS, & Riley WT (2008). Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. *Nicotine & Tobacco Research* 10(12), 1691-1715.
6. Canadian Tobacco Use Monitoring Survey (2010). http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_ctums-esutc_2010/ann-eng.php#t8
7. Health Canada, First Nations, Inuit and Aboriginal Health <http://www.hc-sc.gc.ca/fniah-spnia/substan/tobac-tabac/index-eng.php>
8. Martens P, Bartlett J, Burlan E, Prior H, Burchill C, Huq S, Romphf L, Sanguins J, Carter S & Bailly A (2010). Profile of Metis health status and healthcare utilization in Manitoba: A population- based study. Manitoba Centre for health Policy in collaboration with the Manitoba Métis Federation, June 2010. Winnipeg.
9. Heart & Stroke Foundation Manitoba (2010). Making the case for primary prevention: An economic analysis of risk factors in Manitoba. Winnipeg.
10. Kahn R, Robertson RM, Smith R, & Eddy D (2008). The impact of prevention on reducing the burden of cardiovascular disease. *Circulation*, 118: 576-85.
11. Lightwood J (2003). The economics of smoking and cardiovascular disease. *Progress in Cardiovascular Diseases*, 46(1), 39-78.

12. Benowitz NL (2003). Cigarette smoking and cardiovascular disease: Pathophysiology and implications for treatment. *Progress in Cardiovascular Diseases*, 46(1), 91-111.
13. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, & Baker T (1997). Cost-effectiveness of the Clinical Practice Recommendations in the AHCPR Guideline for Smoking Cessation. *JAMA*, 278: 1759-66.
14. Mosby Elsevier (2008). *Mosby's Dental Dictionary, 2nd edition*. St. Louis, MO: Mosby Elsevier.
15. American Psychiatric Association (2000). *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)*. Arlington, VA: American Psychiatric Association.
16. Fiore MC, Jaen CR, Baker TB, et al (2008). *Treating Tobacco Use and Dependence: 2008 Update*. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008. http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf
17. O'Donnell DE, Aaron S, Bourbeau J, et al (2007). Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. *Canadian Respiratory Journal*, 14(Suppl B):5B-32B.
18. O'Donnell DE, Hernandez P, Kaplan A, et al (2008). Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. *Canadian Respiratory Journal*, 15(Suppl A):1A-8A.
19. Registered Nurses Association of Ontario (2007). *Integrating Smoking Cessation into Daily Nursing Practice*. Toronto, Canada: Registered Nurses Association of Ontario. <http://www.tobaccofreernao.ca/en/resources/best-practices-guidelines/integrating-smoking-cessation-daily-nursing-practice-summary-rec>
20. Rice VH, Stead LF (2008). Nursing interventions for smoking cessation. *Cochrane Database of Systematic Reviews*, Issue 1. Art. No.: CD001188. DOI: 10.1002/14651858.CD001188.pub3.
21. Rigotti NA, Munafò MR, Stead LF (2007). Interventions for smoking cessation in hospitalized patients. *Cochrane Database of Systematic Reviews*, Issue 3. Art. No.: CD001837. DOI: 10.1002/14651858.CD001837.pub2.
22. NICE (March 2006) Public health intervention guidance no.1 – Brief interventions and referral for smoking cessation in primary care and other settings. http://www.nice.org.uk/nicemedia/pdf/PH001_smoking_cessation.pdf

23. CAN-ADAPTT (2011). *Canadian Practice-Informed Smoking Cessation Guideline*. Toronto, Canada: Canadian Action Network for the Advancement, Dissemination and Adoption of Practice- informed Tobacco Treatment, Centre for Addiction and Mental Health.
24. Fiore MC, Bailey WC, Cohen SJ, et al (2000). *Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation*. US Department of Health and Human Services, Public Health Service.
25. White AR, Rampes H, LiuJP, Stead LF, Campbell J. Acupuncture and related interventions for smoking cessation. *Cochrane Database of Systemic Reviews* 2011 Jan 19;(1):CD000009. doi: 10.1002/14651858.CD000009.pub3.
26. Barnes J, Dong CY, McRobbie H, Walker N, Mehta M, Stead LF. Hypnotherapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2010, Issue 10. Art. No.: CD001008. DOI: 10.1002/14651858.CD001008.pub2.
27. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2012, Issue 11. Art. No.: CD000146. DOI: 10.1002/14651858.CD000146.pub4.
28. Shah et al (2008). Systematic review and meta-analysis of combination therapy for smoking cessation. *Journal of the American Pharmacists Association*, 48(5), 659-65.
29. Silagy C, Lancaster T, Stead L, Mant D, Fowler, G (2004). Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews* 2004, Issue 3. Art. No.: CD000146. DOI:10.1002/14651858.CD000146.pub2.,
30. Hughes, JR, Adams, EH, Franzon, MA, Maguire, MK, Guary, J. A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler. *Tobacco Control*, 2005; 14: 49-54.
31. Nicorette. Nicorette Quickmist. 2012; Available at: <http://www.nicorette.ca/stop-smoking/products/quickmist>. Accessed 09 Sept 2012.
32. Kraiczi H, Hansson A, Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. *Nicotine Tob Res* 2011 Dec;13(12):1176-1182.
33. Lexidrugs. Nicotine: Drug Information. 2012; Available at: http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/nicotine-drug-information?source=search_result&search=nicotine&selectedTitle=1%7E150. Accessed 09 Sept 2012.

34. Ely PB, Kobayashi LA, Campos JHO, Gomes HC, Juliano Y, Gerreira LM (2009). Nicotine on rat TRAM flap: *Acta Cir Bras* [online]. vol.24, n.3, pp. 216-220. ISSN 1678-2674. <http://dx.doi.org.proxy2.lib.umanitoba.ca/10.1590/S0102-86502009000300010>.
35. Forrest CR, Pang CY, Lindsay WK (1991). Pathogenesis of ischemic necrosis in random pattern skin flaps induced by long-term low-dose nicotine treatment in the rat. *Plast Reconstr Surg*;87(3):518-28.
36. Rees TD, Liverett DM, Guy CL (1984). The effect of cigarette smoking on skin flap survival in the face lift patient. *Plast Reconstr Surg* 1984; 73(6) 911-5.
37. Cartin-Ceba R, Warner DO, Hays JT, Afessa B (2011). Nicotine replacement therapy in critically ill patients: a prospective observational cohort study; *Critical Care Medicine*; July;39(7);1635-40.
38. Lucidarme O, Seguin A, Daubin C, Ramakers M, Terzi N, Beck P, Charbonneau P, du Cheyron D (2010). Nicotine withdrawal and agitation in ventilated critically ill patients. *Crit Care*;14(2)R58.
39. Seder DB, Schmidt JM, Badjatia N, Fernandez L, Rincon F, Claassen J, Gordon E, Carrera E, Kurtz P, Lee K, Connolly ES, Mayer SA (2011). Transdermal nicotine replacement therapy in cigarette smokers with acute subarachnoid hemorrhage. *Neurocrit Care*; February;14(1):77-83.
40. Lee AH, Afessa B (2007). The association of nicotine replacement therapy with mortality in a medical intensive care unit. *Critical Care Medicine*;June;35(6)1517-21.
41. Najem B, Houssiere A, Pathak A, Janssen C, Lemogoum D, Xhaet O, Cuylits N, van de Borne P (2006). Acute Cardiovascular and sympathetic effects of nicotine replacement therapy. *Hypertension*;2006;47;1162-67.
42. Moghaddam A, Weiss S, Wöfl CG, Schmeckenbecher K, Wentzensen A, Grütznier PA, Zimmermann G (2010). Cigarette smoking decreases TGF- β 1 serum concentrations after long bone fracture. *Injury*; 41(10):1020-5.
43. Krannitz KW, Fong HW, Fallat LM, Kish J (2009). The effect of cigarette smoking on radiographic bone healing after elective foot surgery. *The Journal of Foot and Ankle Surgery*. 48(5):525-7.
44. Little CP, Burston BJ, Hopkinson-Woolley J, Burge P (2006). Failure of surgery for scaphoid non-union is associated with smoking. *J Hand Surg Br*. 31(3):252-5.
45. Raikin SM, Landsman JC, Alexander VA, Froimson MI, Plaxton NA (1998). Effect of

nicotine on the rate and strength of long bone fracture healing: *Clin Orthop Relat Res*:August; (353):231-7.

46. Ontario Medical Association (2008). OMA Position Paper: Rethinking Stop-Smoking Medications: Treatment Myths and Medical Realities (Jan.08) Toronto, ON. Available at:
<https://www.oma.org/Resources/Documents/e2008RethinkingStop-SmokingMedications.pdf>
47. Krueger JK & Rohrich RJ (2001). The scientific rationale for tobacco abstinence in plastic surgery. *Plast Reconstr Surg*; 108(4); 1063-73.
48. Meyer JM (2001). Individual changes in clozapine levels after smoking cessation: results and a predictive model. *Journal of Clinical Psychopharmacology* 21(6):569-74.
49. Chan LKW, Withey S & Butler PEM (2006). Smoking and wound healing problems in reduction mammoplasty: Is the introduction of urine nicotine testing justified? *Ann Plast Surg*; 56(2): 111-5.
50. Kuri M, Nakagawa M, Tanaka H, Hasuo S & Kishi Y (2005). Determination of the duration of preoperative smoking cessation to improve wound healing after head and neck surgery. *Anesthesiology*; 102(5):892-6.
51. Lexidrugs. Bupropion: Drug Information. 2012; Available at:
http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/bupropion-drug-information?source=search_result&search=bupropion&selectedTitle=1%7E88. Accessed 09 Sept 2012.
52. Lexidrugs. Varenicline: Drug Information. 2012; Available at:
http://www.uptodate.com.proxy2.lib.umanitoba.ca/contents/varenicline-drug-information?source=search_result&search=varenicline&selectedTitle=1%7E22. Accessed 09 Sept 2012.
53. Pfizer Canada. Champix Product Monograph (14 Dec 2011). Available at:
www.pfizer.ca/en/our_products/products/patient_infosheet/152 Accessed 24 Oct 2012.

Appendix A

Grade of Recommendation & Level of Evidence Summary Table for CAN-ADAPTT Summary Statements

GR/LOE*	CLARITY OF RISK/BENEFIT	QUALITY OF SUPPORTING EVIDENCE	IMPLICATIONS
1A Strong Recommendation <i>High Quality Evidence</i>	Benefits clearly outweigh risk and burdens, or vice versa	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.	Strong recommendations, can apply to most patients in most circumstances without reservation. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.
1B Strong Recommendation <i>Moderate Quality Evidence</i>	Benefits clearly outweigh risk and burdens, or vice versa	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.	Strong recommendation and applies to most patients. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.
1C Strong Recommendation <i>Low Quality Evidence</i>	Benefits appear to outweigh risk and burdens, or vice versa	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.	Strong recommendation, and applies to most patients. Some of the evidence base supporting the recommendation is, however, of low quality.
2A Weak Recommendation <i>High Quality Evidence</i>	Benefits closely balanced with risks and burdens	Consistent evidence from well performed randomized, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change our confidence in the estimate of benefit and risk.	Weak recommendation, best action may differ depending on circumstances or patients or societal values
2B Weak Recommendation <i>Moderate Quality Evidence</i>	Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens	Evidence from randomized, controlled trials with important limitations (inconsistent results, methodologic flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on our confidence in the estimate of benefit and risk and may change the estimate.	Weak recommendation, alternative approaches likely to be better for some patients under some circumstances
2C Weak Recommendation <i>Low Quality Evidence</i>	Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens	Evidence from observational studies, unsystematic clinical experience, or from randomized, controlled trials with serious flaws. Any estimate of effect is uncertain.	Very weak recommendation; other alternatives may be equally reasonable.

* GR- Grade of Recommendation, LOE – Level of Evidence

** Adapted from: UpToDate. Grading guide. No date. Available from: <http://www.uptodate.com/home/about/policies/grade.html>; and Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an American College of Chest Physicians task force. *Chest*. 2006 Jan;129(1):174-81, originally adapted from the GRADE Working Group.